Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04028440 | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | unknown | Early Phase 1 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT02060656 | Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)(LEGEND) | unknown | Phase 2 | 92 | Royal Marsden NHS Foundation TrustOTHER | 1 |
| Sep 19, 2019 |
| clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT03618602 | Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients | unknown | Phase 1 | 30 | Shanghai Theorion Pharmaceutical Co Ltd.INDUSTRY | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04094051 | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice | unknown | — | 580 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT04083066 | Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03497533 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19(Trident19-H) | unknown | Phase 1 / Phase 2 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT04066920 | IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL | unknown | Phase 2 | 30 | Deok-Hwan YangOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT04065308 | Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma(Dara_DCEP) | unknown | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT04063189 | Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | unknown | Phase 2 | 100 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04056975 | Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma(A-319) | unknown | Phase 1 | 54 | EVIVE BiotechnologyINDUSTRY | 0 | Aug 14, 2019 | clinicaltrials |
| NCT03598179 | XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | unknown | Phase 2 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04007978 | Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04008251 | Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 | 10 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04048395 | Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea(FLPOD24) | unknown | — | 80 | Samsung Medical CenterOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04037566 | CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. | unknown | Phase 1 | 40 | Xijing HospitalOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT03715296 | Lenalidomide Based Immunotherapy in the Treatment of DLBCL | unknown | — | 200 | Ruijin HospitalOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03715309 | R2 in the Treatment of Follicular Lymphoma | unknown | Phase 2 | 115 | Ruijin HospitalOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03815383 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 12 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT04008888 | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients | unknown | N/A | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT04004338 | Carfilzomib in Combination for the Treatment of RR MM | unknown | — | 300 | Black Sea Hematology AssociationOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT02976272 | Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple(SENSIB) | unknown | — | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 1, 2019 | clinicaltrials |
| NCT03999697 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02954445 | A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03992170 | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive(DART4MM) | unknown | Phase 2 | 50 | Azienda Ospedaliera Universitaria SeneseOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03931421 | B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03971565 | Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leukemia(LLC) | unknown | — | 47 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03777085 | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | unknown | Phase 3 | 230 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2019 | clinicaltrials |
| NCT03751293 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02965092 | CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 80 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03366350 | Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 50 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03940833 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03588598 | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | unknown | Phase 1 | 40 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03929107 | Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. | unknown | Phase 2 | 80 | Wenbin QianOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03569696 | Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy(NivoM) | unknown | Phase 2 | 50 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03881761 | CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma | unknown | Phase 1 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03881774 | Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03881592 | Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness(GO-CLLEAR) | unknown | — | 400 | Brno University HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02652910 | Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma(MeCAR) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03093168 | BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma | unknown | Phase 1 | 10 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03854994 | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Yan'an Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02842138 | Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 25 | Peking UniversityOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT01670370 | Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 15, 2019 | clinicaltrials |
| NCT03258047 | Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | unknown | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01240525 | Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers(ProT4) | unknown | Phase 2 | 114 | University College, LondonOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT00863460 | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients(PRECIS) | unknown | Phase 2 | 140 | Institut CurieOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT03000335 | Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk | unknown | — | 65 | Curewize Health Ltd.INDUSTRY | 1 | Feb 4, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Sep 26, 2019source: clinicaltrials